

Trobix Bio Receives Patent Allowance in the USA

Netanya, Israel, May 04, 2021

Netanya, Israel. Trobix Innovation Ltd. ([Trobix Bio](#)), an Israeli-based biotechnology company developing precision microbiome-based therapies to remove the threat of antimicrobial resistance, announces that it has received from the United States Patent and Trademark Office (USPTO) a Notice of Allowance for its licensed US patent application 15/605,098 titled “targeted elimination of bacterial genes”. The allowed patent application covers kits and methods of using CRISPR technology to eliminate bacterial genes that confer antibiotic resistance and select for such bacteria that are now antibiotics sensitive.

“We are excited to receive a USA patent allowance for this key patent family”, said Dr. Adi Elkeles, Founder & CEO of Trobix Bio. “The claims granted by the USPTO provide Trobix Bio with broad-based protection in the US, an important target market”, he added.

About Trobix Bio

Trobix Bio, a biotechnology company, with a vision to develop products that engineer the human microbiome and address critical unmet needs such as the threat of antimicrobial resistance. The company is leveraging its platform ActiSense™ CRISPR and GoTrap™ delivery technologies to develop phage-based products that can effectively deliver DNA to a wide range of bacterial pathogens and actively sensitize these pathogens to antibiotics. The company’s lead product, TBX101, targets patients carrying gut antimicrobial resistant bacteria, resulting in an antibiotic sensitive gut microbiome.

For more information, please contact:

Dr. Adi Elkeles

CEO & co-Founder

Trobix Bio

Tel: +972-54-6402333

Email: adie@trobixbio.com